ArticleToxicon : official journal of the International Society on Toxinology2007
Inhibition of melanoma cell motility by the snake venom disintegrin eristostatin.
Article in Toxicon : official journal of the International Society on Toxinology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 46 citations in OpenAlex.
- A Novel P-III Metalloproteinase fromToxins · 2024Article
- Snake venom disintegrins update: insights about new findings.The journal of venomous animals and toxins including tropical diseases · 2023Review
- Review
- Cell migration inhibition activity of a non-RGD disintegrin fromThe journal of venomous animals and toxins including tropical diseases · 2018Article
- Inhibition of αvβ3 integrin induces loss of cell directionality of oral squamous carcinoma cells (OSCC).PloS one · 2017Article
- Evaluation of cytotoxic activities of snake venoms toward breast (MCF-7) and skin cancer (A-375) cell lines.Cytotechnology · 2016Article
- Disintegrins from snake venoms and their applications in cancer research and therapy.Current protein & peptide science · 2015Review
- Applications of snake venom components to modulate integrin activities in cell-matrix interactions.The international journal of biochemistry & cell biology · 2013Review
- Effect of the disintegrin eristostatin on melanoma-natural killer cell interactions.Toxicon : official journal of the International Society on Toxinology · 2013Article
- Anti-invasive and anti-adhesive activities of a recombinant disintegrin, r-viridistatin 2, derived from the Prairie rattlesnake (Crotalus viridis viridis).Toxicon : official journal of the International Society on Toxinology · 2012Article
- Engineered mammalian vector to express EGFP-tagged proteins as biomarkers.Molecular biotechnology · 2012Article
- Plexin B1 inhibits integrin-dependent pp125FAK and Rho activity in melanoma.Pigment cell & melanoma research · 2011Article
- Snake venom disintegrins and cell migration.Toxins · 2010Review
- The mojastin mutant Moj-DM induces apoptosis of the human melanoma SK-Mel-28, but not the mutant Moj-NN nor the non-mutated recombinant Moj-WN.Toxicon : official journal of the International Society on Toxinology · 2010Article
Corrections and comments
- Erratum issued
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Eristostatin, an RGD-containing disintegrin isolated from the venom of Eristicophis macmahoni, inhibits lung or liver colonization of melanoma cells in a mouse model. In this study, transwell migration and in vitro wound closure assays were used to determine the effect of eristostatin on the migration of melanoma cells. Eristostatin significantly impaired the migration of five human melanoma cell lines. Furthermore, it specifically inhibited cell migration on fibronectin in a concentration-dependent manner, but not that on collagen IV or laminin. In contrast, eristostatin was found to have no effect on cell proliferation or angiogenesis. These results indicate that the interaction between eristostatin and melanoma cells may involve fibronectin-binding integrins that mediate cell migration. Mutations to alanine of seven residues within the RGD loop of eristostatin and four residues outside the RGD loop of eristostatin resulted in significantly less potency in both platelet aggregation and wound closure assays. For six of the mutations, however, decreased activity was found only in the latter assay. We conclude that a different mechanism and/or integrin is involved in these two cell activities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.